A Post-Hoc Analysis of Emotional Lability With Delayed-Release/Extended-Release Methylphenidate in Children Aged 6 to 12 Years of Age Participating in Two Phase 3 Clinical Trials
Journal of Attention Disorders · 2024-06 · 28 (8) · 1186-1197
DOI: 10.1177/10870547241243155 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Attention Disorders, online erschienen am 10.04.2024. Verfasst von Valerie K Arnold und 7 weiteren Autor:innen. Beteiligte Einrichtung: UTHSC Center on Developmental Disabilities, Memphis, TN, USA. Hauptthemen laut MEDLINE: Methylphenidate, Delayed-Action Preparations, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ironshore.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objective
DR/ER-MPH (formerly HLD200) is an evening-dosed delayed-release and extended-release methylphenidate approved for the treatment of ADHD in patients ≥6 years. Post hoc analyses of two pivotal Phase 3 trials: HLD200-107 (NCT02493777) and HLD200-108 (NCT02520388) evaluated emotional lability (EL) with DR/ER-MPH treatment.
Methods
Differences in Conners Global Index—Parent (CGI-P) EL subscale scores and age- and gender-adjusted T-scores over an open-label titration phase (HLD200-107) and between treatment and placebo groups at endpoint (HLD200-108) were evaluated.
Results
In HLD200-107 ( N = 117) mean CGI-P EL subscale scores improved from 5.3 to 1.3 ( p < .0001) after 6 weeks; in HLD200-108 significant improvements were observed in the treatment group ( n = 81) versus placebo ( n = 80; 3.11 vs. 4.08; p = .0053). T-scores showed an improvement with DR/ER-MPH treatment in both trials. Few emotional adverse events (AEs) were reported.
Conclusion
DR/ER-MPH treatment resulted in statistically significant improvements in EL to the level of non-ADHD peers as contextualized by T-scores.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UTHSC Center on Developmental Disabilities, Memphis, TN, USA.
- Pediatrix Neurology and Epilepsy Research Center, Winter Park, FL, USA.
- Center for Psychiatry and Behavioral Medicine Inc., Las Vegas, NV, USA.
- Ironshore, Camana Bay, Grand Cayman, Cayman Islands.
ORCID-Profile: Michelle D Po, Cassandra L Uchida, Lewis Cuthbertson
Förderung
- Ironshore
Zitieren
APA
Arnold, V. K., López, F. A., Childress, A. C., Po, M. D., Uchida, C. L., Cuthbertson, L., Sallee, F. R., & Incledon, B. (2024). A Post-Hoc Analysis of Emotional Lability With Delayed-Release/Extended-Release Methylphenidate in Children Aged 6 to 12 Years of Age Participating in Two Phase 3 Clinical Trials. Journal of Attention Disorders, 28(8), 1186-1197. https://doi.org/10.1177/10870547241243155
Vancouver
Arnold VK, López FA, Childress AC, Po MD, Uchida CL, Cuthbertson L, et al. A Post-Hoc Analysis of Emotional Lability With Delayed-Release/Extended-Release Methylphenidate in Children Aged 6 to 12 Years of Age Participating in Two Phase 3 Clinical Trials. Journal of Attention Disorders. 2024;28(8):1186-1197. doi:10.1177/10870547241243155
BibTeX
@article{Arnold2024,
author = {Arnold, Valerie K and López, Frank A and Childress, Ann C and Po, Michelle D and Uchida, Cassandra L and Cuthbertson, Lewis and Sallee, Floyd R and Incledon, Bev},
title = {A Post-Hoc Analysis of Emotional Lability With Delayed-Release/Extended-Release Methylphenidate in Children Aged 6 to 12 Years of Age Participating in Two Phase 3 Clinical Trials},
journal = {Journal of Attention Disorders},
year = {2024},
volume = {28},
number = {8},
pages = {1186--1197},
doi = {10.1177/10870547241243155}
}
EUVIMED